chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Beginning 2 hours after receiving my second dose of Pfizer vaccine, I experienced mild frontal headache, body aches, and joint aches of mild intensity (elbows, wrists/hands, knees, ankles/feet). No fever. I took two tablets of extra-strength Tylenol every six hours. Early in the morning of 1/15/2021, I had a moderately-intense headache in the frontal region and felt like my temples were being squeezed.
nausea, vomiting, diaphoresis, dizziness, headaches, bilateral tranverse sinus thrombosis
9-29-15 pt had vaccine returned around 20 min later showed me, 2 x 2 round swollen area 1-1 1/2" below vaccination site ice was applied.
I got a very fine, very itchy rash across the top of my back and on my right leg/shin that eventually went to my left leg. I applied lotion. It didn't go down. It lasted for several days.
arm was sore at the injection site for a few days; underneath her arm it became sore and stayed that way and it spread to the side of her breast around her ribs; swollen lymph nodes; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 78-year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 05Mar2021 (Lot number: EL9264) at the age of 78 years as dose 2, single for covid-19 immunization.   Relevant medical history included: "Blood pressure high" (unspecified if ongoing); "Diabetic" (unspecified if ongoing). Concomitant medication(s) included: IRBESARTAN; METFORMIN; HYDROCHLOROTHIAZIDE.  The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "arm was sore at the injection site for a few days"; PAIN (non-serious), outcome "unknown", described as "underneath her arm it became sore and stayed that way and it spread to the side of her breast around her ribs"; LYMPHADENOPATHY (non-serious), outcome "unknown", described as "swollen lymph nodes".  Additional information: The patient received the second dose of vaccine on 05MAR2021, her arm was sore at the injection site for a few days, but then underneath her arm it became sore and stayed that way and it spread to the side of her breast around her ribs. Patient heard that the vaccine could affect the lymph glands, she consulted a pediatrician who did mention about having a lymph nodes "something". Patient would like to know if this will go away and if the swollen lymph nodes are supposed to last 10 days. Consumer stated that she received antacid pill twice a day it is an just over the counter. The patient had blood work at doctor's office but that was in general for what he was treated and not in reference to the shot.  No follow-up attempts are possible. No further information is expected.
Patient was administered with a vaccine which was keep in the freezer longer than the 2 week recommended time.
Experienced immediate pain radiating from injection site.  Pain got progressively worse over next 24 hours to point where I could not lift my arm.  Pain has continued since and I cannot lift my right arm over my head.
Shot on Tues. Tues. night headache, Wed. headache & fever 100' & weakness & dizzy. All day Wed. Thurs. stomach upset - painful to touch - weakness Sunday - took shower & almost pasted out, from over heating. 2 hrs. Later put 2 Advil in mouth and thought I would vomit - Didn't come to hospital @ 4:30ish.
Accidentally mixed MCV4 thinking it was sterile water and added to the MMR. Injected the mixture of MMR and MCV4 subciutaneous into the right arm. No adverse events reported at this time. Youth says site is sore.
received Vx then shingles were re-activated/suspected vaccination failure; shingles reactivated; This case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a 80-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (had a history of shingles).   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.  Additional Information: GSK Receipt Date: 03-MAR-2023 Reporter's Comment: The reporter stated that her friend's mother who had a history of shingles received the Shingrix vaccine and her shingles were re- activated after Shingrix.  She thought that it might have already been reported, this was a while ago.  She did not want to provide any additional information. Limited information was reported. The reporter did not consent to follow-up. Additional Supportive Information: This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.
FELT DIZZY AND SLID DOWN IN THE CHAIR. WAS IMMEDIATELY LAYED ON THE FLOOR. BLOOD PRESSURE 76/48 @ 9:36 PULSE 64 PALE AND SLIGHTY DIAPHORETIC. COOL CLOTH TO FOREHEAD. 9:40 BLOOD PRESSURE 78/48 PULSE 62
Patient received 1st dose of Moderna vaccine on 3.15.2021. Approximately 3 minutes after receiving the vaccine, the patient had what appeared to be an epileptic seizure. Patient lowered to the ground with a pillow, provider called, nursing and pharmacy present. O2 sat 99%, pulse 73, and BP 116/42. Patient continued to have seizure, EMS called. Ambulance arrived shortly thereafter, BP 146/58, sats 99%, and pulse 72. Patient quit having epileptic activity at this point. Patient does have a history of non-epileptic seizures from stress, bright flashing lights, etc. Patient assisted to wheelchair and taken to private room with staff. Patient discharged from clinic at 1200, refused transfer via EMS, given warning precautions for when to seek emergency care.
Shingrix 4 years ago and is late for the 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose 4 years ago).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Shingrix 4 years ago and is late for the 2nd dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 24-JUL-2023 The reporter reported that a patient received the 1st dose of Shingrix 4 years ago and was late for the 2nd dose. The healthcare professional did not have exact date of vaccination (and only stated that the patient received it 4 years ago), lot, or expiration. The patient's DOB (date of birth) was not asked. The reporter consented to follow up via email. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
Vertigo; Trembling; Upper body rash/ I had a reaction like a rash that last for three days in my upper body; Fever; Chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 68 year-old female patient received bnt162b2 (BNT162B2), administration date 20Feb2021 (Lot number: EN6201) at the age of 68 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Cancer" (unspecified if ongoing), notes: It's been ten years since, I had cancer treatment; "Vertigo" (unspecified if ongoing). Concomitant medication(s) included: LIPITOR. Vaccination history included: Bnt162b2 (DOSE: 1, Batch/lot number: EL8982), administration date: 30Jan2021, when the patient was 68 years old, for COVID-19 immunization. The following information was reported: RASH (non-serious) with onset 20Feb2021, outcome "recovered" (23Feb2021), described as "Upper body rash/ I had a reaction like a rash that last for three days in my upper body"; PYREXIA (non-serious) with onset 20Feb2021, outcome "recovered" (Feb2021), described as "Fever"; CHILLS (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "Chills"; TREMOR (non-serious) with onset 20Feb2021, outcome "recovered" (Feb2021), described as "Trembling"; VERTIGO (non-serious) with onset Mar2021, outcome "unknown", described as "Vertigo". Therapeutic measures were taken as a result of rash, pyrexia, chills, tremor, vertigo.  Additional information: She have had 2 doses of the Pfizer BTC Vaccine and with the 2nd dose the patient reported she had an upper body rash that lasted more than 3 days, fever that lasted 6 hours with chills. She asked Should she pre medicate, for the rash before she gets her Pfizer BTC vaccine booster dose? The patient stated she always pre medicates before she has any scans that involve iodine contrast. Therapeutic measures were taken as a result of events with Panadol.   No follow-up attempts are possible. No further information is expected.
a little rash on my arm and it won't stop itching; a little rash on my arm and it won't stop itching; This is a spontaneous report from a contactable consumer reporting for himself. A 61-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration on 10Mar2021 (Batch/Lot Number: EW6208) as a single dose (at the age of 61 years old), and dose 2 via an unspecified route of administration on 31Mar2021 (Batch/Lot Number: ERB731) as a single dose (at the age of 61 years old) for COVID-19 immunisation. Relevant medical history was not provided. Concomitant medication included a lot of unspecified medication. On an unspecified date, the patient experienced a little rash on my arm and it won't stop itching. Therapeutic measures were taken as a result of a little rash on my arm and it won't stop itching included diphenhydramine (BENADRYL). The patient reported that he took diphenhydramine to stop it but it's still right there. The outcome of the event a little rash on my arm and it won't stop itching was not recovered.  Information on Lot/Batch number was available. Additional information has been requested.
This spontaneous report was received from a health professional refers to two unspecified patients of unknown demographics. The pertinent medical history of patients and their concurrent conditions were not reported. On an unknown date in JUL-2015 the patients were vaccinated with improperly stored GARDASIL (lot # K007264, expiry date: 02-MAR-2017) dose, route unknown. Concomitant medications were not reported. No adverse effects were reported. This is one of the two reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. On an unknown date the patients were vaccinated with the doses of improperly stored GARDASIL (lot # K008931, expiration date: 04-MAR-2017. doses and routes were not reported and lot # K023432, expiration date: 18-JUN-2016, doses and routes not reported). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
pt recvd vax; lymphadenopathy, dizziness, redness, pain, itching, swelling & warmth at site p/ dose 1; pre tx w/ dph & apap dose 2 & 3; local rxn dose 2;
said that her throat felt swollen. I gave her a dose of benadryl and some water. She said she felt better
Extreme vertigo lasting several hours each day from April 10 to April 19, including trip to hospital ER and brain MRI Prescribed Meclizine, Valium, and Prednisone
Patient approached consultation area, and appeared tired. I approached her and she fell down slowly, and was down for a couple of seconds. I went up to her and made sure she was okay, asked her if she had any trouble breathing. She had no trouble breathing, however she felt nauseous and lightheaded. We got her water and asked if she wanted anything to eat.
bilateral hearing loss 10 days after; This is a spontaneous report from a contactable consumer (the patient is reporter's mother). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced bilateral hearing loss 10 days after receiving the Pfizer vaccine. Hearing returned in one ear. Hearing remained intermittent in the other ear. Patient did not have inflamed auditory nerve. Patient is currently undergoing testing for Meniere's disease. The outcome of event was recovering.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
7 year old female patient received a dose; Patient's 4th dose of DTAP in the schedule.; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 7-year-old female patient who received DTPa (Infanrix) (batch number 4L9E4, expiry date 7th February 2023) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Infanrix (received 1st, 2nd and 3rd dose on an unknown date).   On 22nd April 2022, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 22nd April 2022, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration and drug dose administration interval too long. On an unknown date, the outcome of the inappropriate age at vaccine administration and drug dose administration interval too long were unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 22-APR-2022 Reporter's Comments: A physician assistant reported that a 7 year old female patient received a dose of Infanrix. It was the patient's 4th dose of DTAP in the schedule. The reporter consented to follow up. Additional Supportive Information: The 7 year old patient received 4th dose of Infanrix, which led to inappropriate age at vaccine administration and lengthening of vaccination schedule.
slightly sore left arm (2nd dose); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (slightly sore left arm (2nd dose)) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Seasonal Flu vaccine (Seasonal flu vaccine sometime in 2021.) in 2021. Past adverse reactions to the above products included No adverse event with Seasonal Flu vaccine. Concurrent medical conditions included Seafood allergy (Shrimp) and Seafood allergy (Lobster). Concomitant products included VITAMIN D [VITAMIN D NOS] and ASCORBIC ACID, BETACAROTENE, CUPRIC OXIDE, TOCOPHERYL ACETATE, ZINC OXIDE (PRESERVISION) for an unknown indication.   On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 26-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 26-Feb-2021, the patient experienced VACCINATION SITE PAIN (slightly sore left arm (2nd dose)). At the time of the report, VACCINATION SITE PAIN (slightly sore left arm (2nd dose)) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant medication details include PreserVision Vitamin, Unknown low dose blood pressure medication for use as a preventative.  No treatment details were reported.   This case was linked to MOD-2022-533466, MOD-2022-533479 (Patient Link).   Reporter did not allow further contact
Patient claimed swelling, soreness, and heat at injection site the following day. Patient went to promt-care two days later said his white cell count was elevated.
Patient received SHINGRIX vaccine on 11/15/2018. The next morning she awoke with chills and nausea and feeling her her head was heavy. She then had a syncopal episode. No cardiac or neurologic symptoms, no other new meds. Pt was found by housekeeper and EMS was called. They evaluated her and told her glucose and EKG was fine-they fine- they advised ER visit which she declined. I evaluated her in office but by this time was completely asymptomatic. She had has never had a prior syncopal episode.
After second dose feeling very light dizzy; This spontaneous case was reported by a patient and describes the occurrence of DIZZINESS (After second dose feeling very light dizzy) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 02SC21A and 0391321A) for COVID-19 vaccination.     Concomitant products included AMLODIPINE for an unknown indication.   On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-May-2021, the patient experienced DIZZINESS (After second dose feeling very light dizzy). At the time of the report, DIZZINESS (After second dose feeling very light dizzy) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2020, SARS-CoV-2 test: (Positive) Positive.   Action taken with mRNA-1273 in response to the events was not applicable      Concomitant medications include Medicine for cholesterol   This case was linked to MOD-2021-092391 (Patient Link).
I specifically told the pharmacist that this was my first ever Covid vaccine and that i will not take the Johnson and Johnson, but i preferred Pfizer. After being administered the shot, he was like your all done. I said i have to come back for the second dose and specified that i dont need the second dose. I made him aware that my job wants me to have both shots. He stated if thats the case come back in 3 weeks (April 7th, 2023) and he will give me another one. i come back three weeks later, and was told i was given the wrong shot, which i already figured out as soon i walked it and they told me they did not have the shot. Then i started putting the puzzle pieces together myself and figured out i was administered the wrong shot all in all.
pt recvd vax 11AM 22JUN95 & the same day 5PM pt devel a fever & 623PM devel a few spots;one minute later pt had about 20 spots;no further details were provided;
6 hrs p/vax to next day post nausea & vomiting, h/a shooting pain behind eye c/o migraine; resolved w/in 24 hrs;
I noticed after my 2nd vaccine that I had a breakthrough menstrual bleeding mid-cycle and sometimes heavier than others for no reason. It happened the first time in the summer when I first sought care and the doctor said to just watch it and if it became a bigger deal to let her know, but it's been more frequent lately between the 2nd and 3rd dose that it's been happening.
Pt stated that she had a reaction to first Moderna dose consisting of similar symptoms, after which she went home and sxs alleviated by the next day, per pt report.  Today, she describes similar subjective symptoms as being "1/4th" of the first dose symptoms.   States her doctor told her she was okay to come back for 2nd Moderna vaccine dose.  She is accompanied by her father, today.   She took Metoprolol 50 mg this morning, as well as Metformin 1000 mg and her iron pill today.     Today, she complains of headache 5-8/10 and 5/10 chest tightening at center of chest.  States she feels a bit anxious, given situation.  Provided pt with quiet place to check vitals.   Initial BP 144/78 with pulse ox of 99, HR 72.  Chest tightness. dulled within 10 min of initial symptoms.  Throbbing headache worsened slightly to 8/10 at left side of head.    Pt left facility with BP of 134/83, HR 69, and RA of 98%.  Chest tightness alleviated and headache continued.  Pt left facility in stable condition with her parents.
Little bumps in cheek area, on the back, thigh area, across the shoulder; Rash that she developed 4 to 5 days after getting 2nd dose of vaccine; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (Little bumps in cheek area, on the back, thigh area, across the shoulder) and RASH (Rash that she developed 4 to 5 days after getting 2nd dose of vaccine) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Seizure.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In March 2021, the patient experienced SWELLING (Little bumps in cheek area, on the back, thigh area, across the shoulder) and RASH (Rash that she developed 4 to 5 days after getting 2nd dose of vaccine). At the time of the report, SWELLING (Little bumps in cheek area, on the back, thigh area, across the shoulder) and RASH (Rash that she developed 4 to 5 days after getting 2nd dose of vaccine) had not resolved.            Concomitant medication include seizure medication.  Treatment information was not provided.   This case was linked to MOD-2021-213779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 15-Mar-2021: Follow-up received and does not contain any new information.
Initial misuse report received from a healthcare professional on 24 October 2013. A 2-year-old patient whose gender, medical history, and concomitant medication were not reported had received a 0.5 ml dose of FLUZONE (Lot number, expiration date, dose number, route and site of vaccination was not reported) on an unspecified date i.e. overdose. No adverse event was reported. List of documents held by sender: none.
This spontaneous report as received from a consumer (patient's sister) refers to a female patient of unknown age. Concurrent conditions and medical history was not reported. On an unknown date, the patient was vaccinated with M-M-R II injection (dose, route, lot number and frequency not provided). No concomitant therapy was reported. On an unknown date, the patient experienced a seizure (medically significant) after receiving MMR II. Patient sought medical attention and had a office visit on unspecified date. The outcome of seizure was reported as recovered. The causality assessment was not provided by the reporter. Upon internal review convulsion was considered as medically significant. Additional information is not expected.